Cardio-oncology addresses the cardiovascular health of patients with cancer, an area of growing importance as cancer survival rates improve. Nurses play a central role in monitoring, educating, and coordinating care, yet a structured, standardized, competency-based education is lacking. This article describes the development, structure, and implementation of the Cardio-Oncology Nursing Education (CONE) program, a global educational initiative designed to equip nurses with specialized knowledge and skills to manage cardiovascular complications in patients with cancer. The CONE curriculum was developed by an international, multidisciplinary committee, informed by a global nursing learning-needs assessment. It comprises 27 virtual modules, providing 18.25 nursing contact hours, including 10.25 pharmacotherapeutics credits accredited by the American Nurses Credentialing Center, aligned with contemporary evidence-based guidelines. Modules cover cardiovascular risk assessment, therapy-related toxicity, survivorship, and multidisciplinary care coordination. The CONE program provides a standardized, evidence-based framework for cardio-oncology nursing education, promoting nurse-led, patient-centered care and improving outcomes for cancer survivors. The asynchronous, flexible curriculum addresses global accessibility barriers and supports learner-directed professional development. Future directions include hybrid learning, simulation-based education, and competency-based certification to formalize nursing roles globally.

With early detection and improvements in systemic and local therapies, millions of people are surviving cancer, but for some at a high cost. In some cancer types, cardiovascular disease now competes with recurrent cancer as the cause of death. Traditional care models, in which the cardiologist or oncologist assess patients individually, do not address complex cancer and cardiovascular needs. Nursing disciplines should be an integral part of holistic assessment in cardio-oncology care. To learn what educational needs nurses perceive important for provision of competent cardio-oncology nursing care, we undertook an international survey, aiming to understand their learning needs and preferred learning modalities. A cross-sectional survey was developed by members of the International Cardio-Oncology Society (IC-OS) Nursing Research group. The survey was in English and consisted of 23 questions which include demographic information, clinical specialty (oncology, cardiology, or cardio-oncology), multiple-choice questions related to clinical topics that nurses might be interested in learning, and preferred methods of instruction. Three hundred and twenty-nine responses were received. The majority expressed interest in learning more about cardio-oncology related topics, primarily via pre-recorded webinars (n = 206, 67

Background:Ibrutinib is the only Bruton tyrosine kinase inhibitor (BTKi) with once-daily oral capsule, tablet, and oral suspension formulations approved in the United States across indications of chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, and previously treated chronic graft-versus-host disease, and for mantle cell lymphoma in Europe. Patients with difficulty swallowing capsules or tablets may require alternative formulations or administration options to optimize treatment. Objectives:To evaluate the relative bioavailability of ibrutinib oral suspension relative to capsule or tablet formulations and to examine compatibility for optimal administration methods. Methods:Relative bioavailability of ibrutinib oral suspension was evaluated in healthy volunteers or patients in comparison to capsule or tablet formulations. Dose recovery and delivery, presence of impurities, particle size, and hold time were evaluated after in vitro mock oral suspension administration via syringe and nasogastric and percutaneous endoscopic gastrostomy (PEG) tubes. Results:Clinical bioavailability was comparable for ibrutinib oral suspension and capsules (420 mg/day) under the fasted state in healthy volunteers. Dose-normalized pharmacokinetic values were similar across ibrutinib formulations in patient studies. All evaluated enteral tubes achieved 90%-110% ibrutinib dose recovery regardless of tube type or syringe after 2 × 3 mL water rinses. Oral suspension preservative may be adsorbed into enteral tubes after a 60-minute hold time. Conclusion:Ibrutinib oral suspension bioavailability was comparable with ibrutinib tablet and capsule formulations. When dosed via standard enteral tube administration methods, ibrutinib oral suspension is stable and compatible with polyurethane, silicone, or polyvinyl nasogastric or PEG tubes. To ensure full dose recovery and prevent drug preservative adsorption into tubes, ibrutinib oral suspension should be administered immediately and followed by two rinses of 3 mL of water each. Ibrutinib oral suspension is a viable BTKi treatment option for patients requiring or preferring alternatives to oral capsules and tablets.

Nurses are the “heart of patient care” and in the forefront of the health care delivery for cardio-oncology patients. Nurses play a critical central role in maximizing longitudinal health of cancer patients and survivors through the prevention of cardiovascular complications throughout the patient’s cancer care journey. Nurses function in a variety of roles such as nurse clinicians, advanced practice nurses (APNs)or nurse practitioners (NPs), patient educators, managers, nurse navigators or nurse researchers. The role of nurses, particularly the advanced practice nurses as key members in delivering cardio-oncology care is evolving. However, despite the rapidly increasing growth of cardio oncology programs globally, a pivotal need remains to develop and provide formalized training programs for nurses, NPs and APNs. At present, no formal academic cardio-oncology nurse training program or certification exists. There is clearly more work to be done on the role of nurses in cardio-oncology care. As cardio-oncology evolves to become a key specialty with dedicated services being established across the globe, the role of the nurse in delivering this service is critical and a concerted collaborative approach between the two distinct specialties of cardiology and oncology needs to ensure the nursing workforce is educationally prepared and confident to treat and manage cardio-oncology patients.

This is a phase 2 study on HDMP, ofatumumab, and lenalidomide for TN CLL patients. Forty-five enrolled (median age: 62.6 years) including high-risk features. Best overall response: 96%, complete response: 29%. Median progression-free survival: 54.4 months. Nine patients continued treatment at median follow-up of 61.7 months. Treatment generally well-tolerated, with neutropenia as the most common adverse event. Role in frontline setting remains uncertain. Background: Advancements in frontline therapy and chemotherapy-sparing treatments in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have altered the treatment algorithms of this disease. We present a frontline alternative for treatment- na & iuml;ve (TN) CLL/SLL patients. Methods: This was a single-center, phase 2 study of high -dose methylprednisolone (HDMP) and ofatumumab with lenalidomide and ofatumumab consolidative therapy for all comers with TN CLL/SLL. Treatment was continued until disease progression or intolerable side effects. Patients were assessed for response per iwCLL 2008 cr iter ia after completing cycles 3 and 12. Results: Forty-five patients were enrolled (median age, 62.6 years). High-risk features included del17p (18%), Del11q (22%), and unmutated IGHV gene (76%). Median treatment duration was 32 2 (2 7-75 9) months. Thirty-six patients discontinued treatment due to disease progression (22%), adverse events (40%), allogeneic hematopoietic cell transplantation (allo-HCT) (7%), consent withdrawal (4%), and secondary malignancies (7%). The best overall and complete response rates were 96& and 29% respectively. At median follow-up of 61 7 (5 6-84 9) months, 9 patients remained on treatment. Median progression-free survival was 54 4 (2 9-77 6) months. Three patients underwent allo-HCT after a median of 3 (3-4) treatment cycles. Treatment was well tolerated, with a grade 3/4 infusion reaction in one patient. The most common grade 3/4 hematological adverse event was neutropenia (69%). Four patients had grade 3/4 infections. No grade 3/4 tumor flares, tumor lysis syndrome, or thrombosis were observed. Conclusion: The combination of ofatumumab, HDMP, and lenalidomide was effective and relatively well tolerated in treatment-naive CLL/SLL. Its role in the frontline setting remains unclear given the current available and effective treatment options. Funding: The funders had no role in the study. Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, No. 6, 382-391 (c) 2024 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )

Background: Pirtobrutinib is an oral highly selective noncovalent Bruton tyrosine kinase inhibitor (BTKi) that has shown promising efficacy in heavily treated patients with relapsed/refractory (R/R) B cell lymphomas. We conducted a single-center retrospective study evaluating the safety and tolerability of pirtobrutinib in the real-world setting. Methods: The data for this study was gathered using the prescription records from the outpatient pharmacy at the H Lee Moffitt Cancer Center and Research Institute. All patients who were prescribed pirtobrutinib from June 1st, 2022 to June 1st, 2024 as part of standard-of-care regimens, off-label, or compassionate use were included in this study. All patients received at least one month of treatment with pirtobrutinib. The electronic medical records (EMR) of these patients were then accessed to review their treatment history and tolerance to pirtobrutinib. Data regarding adverse events (AEs) were collected from the medical documentation in the EMR. Descriptive analysis was performed using Statistical Package for the Social Sciences (SPSS) version 28.0. Results: A total of 29 patients received pirtobrutinib. Among these 12 (41.1%) were treated for R/R chronic lymphocytic leukemia (CLL), 11 (37.9%) for R/R mantle cell lymphoma (MCL), 4 (13.8%) for Richter's transformation, and 1 (3.4%) patient each for R/R Waldenström macroglobulinemia and R/R marginal zone lymphoma, respectively. The median age was 72 (interquartile range [IQR] 66.5-76] years. Most patients were male (n=23, 79.3%). This was a heavily treated population with a median 4 (IQR 3-5) prior lines of therapy. All patients had disease progression on a BTKi. Nine (75%) of the CLL patients had disease progression on both a BTKi and venetoclax. Six of these CLL patients had a documented BTK C481 mutation on next-generation sequencing. All patients with MCL had received at least 1 line of chemotherapy and overall, 24 (82.8%) of patients had received prior chemotherapy. A total of 6 (20.7%) patients had received prior chimeric antigen receptor (CAR) T-cell therapy, while 4 (13.8%) had undergone a hematopoietic stem cell transplant before initiating treatment with pirtobrutinib. The median follow-up time was 6 (IQR 3-10.5) months. The median duration of treatment was 4 (2-8.5) months. Ten (34.5%) patients had disease progression on pirtobrutinib. Nine (31.0%) patients received pirtobrutinib as part of the bridging therapy to CAR T- cell therapy. At the time of data cut-off, 12 (41.3%) patients were continuing treatment on pirtobrutinib. The dose of pirtobrutinib was 200 mg daily for 27 patients, while 3 patients were treated with a reduced dose of 100 mg daily due to a personal history of atrial fibrillation and/ or potential drug interactions. In terms of safety, 27 (93.1%) had at least 1 AE of any grade documented in the EMR after initiation of therapy. Most of these were grade I/II AEs (79.3%). The most common AE was fatigue (27.6%), followed by infections (17.2%) and thrombocytopenia (17.2%). Other common grade I/II AEs included hypertension (10.3%), bruising (10.3%), nausea/ vomiting (10.3%), diarrhea (10.3%), anemia (6.9%), and rash (6.9%). Six patients experienced ≥grade 3 AEs. Among them, 4 patients required temporary discontinuation of pirtobrutinib. Two of these were due to severe infection, resulting in sepsis and hospitalization, 1 for neutropenia requiring granulocyte-colony stimulating factor support, and 1 for atrial fibrillation where the drug was later resumed at a reduced dose of 100 mg. No other dose reduction due to AEs were noted. An additional 2 patients permanently discontinued pirtobrutinib due to grade IV hepatic injury and recurrent pleural effusions with negative cytology, respectively. No sudden cardiac deaths were observed. In total, 8 (27.6%) patients died during the study period, of which 6 were directly related to disease progression. Conclusion: The AE profile seen in our real-world data is comparable to that reported in the original clinical trial population suggesting pirtobrutinib is safe and well-tolerated in this high-risk population. Longer-term follow-up with larger multicenter data would be required to determine the true incidence of some rare side effects such as severe hepatic injury and pleural effusions that were recorded in our patient cohort.

Dasatinib is one of the second generation tyrosine kinase inhibitors (TKI) which is approved for the treatment of patients with chronic phase CML (CP-CML) both in the front line and in the second line setting. Pleural effusion (PE) is a unique toxicity associated with dasatinib use. Our aim was to study the incidence of pleural effusion in our cohort of patients who were treated with dasatinib for CP-CML and the safety upon TKI switch. A total of 390 patients were treated with dasatinib during their course of treatment for CP-CML. A total of 69 patients (17.6%) developed any grade of PE. About 33 (48%) patients developed CTCAE grade 2 PE, 34 (49%) grade 3 and only 1 patient developed grade 4 PE. Recurrence of PE was observed in 34 (49%) patients. While only 12 patients (17.3%) continued using dasatinib after development of PE, dasatinib was discontinued in the other 57 patients. Therapy was switched to bosutinib in 13 patients out of which 6 (46%) patients re-developed PE. While only 12.5% patients developed re-accumulation of pleural fluid in patients switched to imatinib, none of the patients switched to nilotinib re-developed PE. A change in TKI to bosutinib was associated with a 46% risk of recurrence of PE in patients who develop PE on dasatinib for the treatment of CP-CML. The incidence of recurrent PE was markedly lower in patient switched to imatinib or nilotinib.

Background: The population of patients with chronic lymphocytic leukemia (CLL) with disease refractory to Bruton tyrosine kinase inhibitors (BTKi) is growing given the widespread use of these agents. We conducted a single center study to evaluate the disease characteristics, treatment strategies, and outcomes for patients with BTK mutation. Methods: The archives of personalized genetic medicine at the H Lee Moffitt Cancer Center and Research Institute were accessed to identify cases of BTK mutation confirmed by next generation sequencing that were reviewed between 2016-2023. Individual records of patients identified were examined to gather data regarding clinical history, genetic testing, and treatment following detection of BTK mutation according to an Institutional Review Board approved protocol. Each patient record was followed for 2 years post detection of BTK mutation or till July 2023, whichever came first, to determine progression free survival (PFS) on next line of therapy. Results: A total of 30 patients were identified. The median age was 67.5 (interquartile range (IQR) 61-73.5) years and 15 (50.0%) of the patients were female. Twenty-three (76.7%) of the patients were on ibrutinib, while 7 (23.3%) were on acalabrutinib. Only 4 (13.3%) patients received BTKi as the first line of therapy. The majority of patients received BTKi as the second line of treatment (46.7%), while 30.3% received it as 3rd line, and 10.0% received it as 4th line. The median time to progression on BTKi 52.5 months. The most common presentation of progression was worsening lymphocytosis alone (36.7%), followed by lymphadenopathy (LAD) and lymphocytosis (33.3%), and LAD alone (20.0%). The most common BTK mutation variant seen was C481S that occurred in 21 (70.0%) cases. C481S mutation occurred independently in the absence of another BTK variant mutation in 18 of these patients. C481R mutation was seen in 20.0% of the cases and was always seen concurrently with another variant mutation (either C481F, C481Y, or C841S). The median number of other mutations present concurrently with BTK mutation was 5 (IQR 3-6). Half (50.0%) of the cases had concurrent TP53 mutation while 30.0% had concurrent PLCG2 mutation. Other commonly seen mutations included NOTCH1 (26.7%), SF3B1 (26.7%), ATM (23.3%), MED12 (16.7%), ASXL1 (16.7%), BIRC3 (13.3%), and TET2 (13.3%) (Figure 1). Following confirmation of BTKi mutation, most patients (63.3%) were started on a venetoclax based regimen. Six patients (20.0%) continued on the same BTKi with addition of venetoclax, 10 (33.3%) patients were switched to venetoclax and immunotherapy (either obinutuzumab or rituximab), and 3 (10.0%) patients were started on single agent venetoclax. Two patients (6.7%) were switched to a non-covalent BTKi while another 2 (6.7%) patients were kept on the same BTKi with the addition of immunotherapy. Three (10.0%) patients were taken to chimeric T cell receptor (CAR-T) cell therapy of which one patient had no response and was started on salvage treatment with duvelisib. Another two patients (6.7%) had Richter's transformation and were treated with chemoimmunotherapy. The overall median PFS for next line of therapy was 18 months with no statistical difference between venetoclax and non-venetoclax regimens (not reached vs 8 months, p=0.25). Conclusion: Our results reveal that durable responses can be achieved by switching to venetoclax based regimens in patients with BTKi. Though the early results of the use of noncovalent BTKi in this setting aree encouraging, the durability of response is limited as new BTK mutations are selected and future therapeutic alternatives are needed for these subset of patients.

OBJECTIVES: To conduct an integrative review of studies to identify disparities in quality of life (QOL), symptoms, and symptom burden between men and women diagnosed with hematologic malignancies. SAMPLE & SETTING: 11 studies comprising 13,546 participants aged 18 years or older were included in the analysis. Studies were original peer-reviewed research published in English between January 2005 and December 2020. METHODS & VARIABLES: A literature search was performed using keywords associated with health-related QOL, hematologic malignancy, and sex/gender differences. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed to identify relevant studies. Data were extracted for sex differences in QOL, symptoms, and symptom burden. All studies were appraised for quality and level of evidence. RESULTS: Women have worse physical health and function, more pain, and higher symptom burden compared with men. IMPLICATIONS FOR NURSING: Healthcare providers need to understand the impact of sex-based differences on QOL, symptoms, and symptom burden to provide optimal, personalized care.

Cardiovascular (CV) risk mitigation is an important consideration in the management of chronic myeloid leukemia (CML) patients. Although BCR-ABL1 inhibition by tyrosine kinase inhibitors (TKI) has led to a significant improvement in prognosis, the majority of CML patients will require indefinite TKI therapy. Given the success of therapy, there has been a shift in focus to include CV care as part of routine patient management. To optimize outcomes, both patient-specific comorbidities and a detailed understanding of the cardiotoxicity safety profiles imparted by each TKI should be considered during agent selection. Clinicians face the challenge of early detection and management of these cardiotoxicities while balancing the risk-benefit ratios of maintaining life-saving cancer therapy. Advanced practitioners play a critical role in CML patient management that extends to the recognition and management of TKI-associated side effects. They should be cognizant of the potential for TKI-associated cardiotoxicities along with appropriate baseline risk assessments, active surveillance, and mitigation strategies as part of a collaborative team effort with cardio-oncologists.

At the 2020 Society of Hematologic Oncology (SOHO) Annual Meeting, William Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, described the clinical implications of measuring minimal residual disease. Lisa Nodzon, PhD, ARNP, AOCNP®, of Moffitt Cancer Center, summarizes the key points for advanced practitioners.

Lisa Nodzon, PhD, ARNP, AOCNP®, of Moffitt Cancer Center, highlights new therapies in development for myelofibrosis that were discussed by Srdan Verstovsek, MD, PhD, of The University of Texas MD Anderson Cancer Center, at the 2020 SOHO Annual Meeting.

Context Accumulating data have shown that several factors influence quality of life (QOL) in oncology patients, making this an important clinical endpoint. Such studies have concluded that gender differences exist for QOL symptoms; therefore, these should be incorporated into clinical decision-making to optimize patient management and improve outcomes. Despite this knowledge, there is a paucity of QOL data characterizing gender differences in hematologic malignancies. Health care providers should be cognizant of this data, as gender differences warrant diverse clinical approaches. Objective The aim of this integrative review is to summarize data from published literature encompassing comparisons of QOL outcomes between men and women diagnosed with any hematologic malignancy and identify knowledge gaps with implications for future intervention-based research aimed at improving QOL symptoms based on the gender of the individual. Methods A systematic literature search using appropriate keywords was conducted in PubMed, CINAHL, and PsycINFO databases to identify research published between 2005 and 2021. Eligibility criteria included studies (1) comparing QOL symptoms as an outcome between men and women with any hematologic malignancy; (2) with patients ≥18 years old; (3) using a validated QOL instrument; and (4) published in English. Manuscripts were screened and extracted using Covidence software and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Results Preliminary search strategy from PubMed, CINAHL, and PsycINFO databases yielded 511 studies meeting eligibility criteria. After selective screening for eligibility criteria and excluding duplicates, nine studies remained for detailed analysis. A review of the published research showed that women reported more pain, greater physical impact of disease and treatment, worse fatigue, fatigue severity with interference, and higher symptom burden compared to men. Level of evidence criteria was defined as being strong if two or more high-quality studies resulted in consistent findings. Conclusions The impact of QOL symptoms based on sex as a biological variable in various hematologic malignancies is an important consideration for providing gender-competent care. Data shows that QOL symptoms differ between genders across several hematologic malignancies. However, research is inadequate regarding the clinical recognition or effective management based on gender. The results of this review will provide information to deliver more personalized and gender-centered care. Accumulating data have shown that several factors influence quality of life (QOL) in oncology patients, making this an important clinical endpoint. Such studies have concluded that gender differences exist for QOL symptoms; therefore, these should be incorporated into clinical decision-making to optimize patient management and improve outcomes. Despite this knowledge, there is a paucity of QOL data characterizing gender differences in hematologic malignancies. Health care providers should be cognizant of this data, as gender differences warrant diverse clinical approaches. The aim of this integrative review is to summarize data from published literature encompassing comparisons of QOL outcomes between men and women diagnosed with any hematologic malignancy and identify knowledge gaps with implications for future intervention-based research aimed at improving QOL symptoms based on the gender of the individual. A systematic literature search using appropriate keywords was conducted in PubMed, CINAHL, and PsycINFO databases to identify research published between 2005 and 2021. Eligibility criteria included studies (1) comparing QOL symptoms as an outcome between men and women with any hematologic malignancy; (2) with patients ≥18 years old; (3) using a validated QOL instrument; and (4) published in English. Manuscripts were screened and extracted using Covidence software and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Preliminary search strategy from PubMed, CINAHL, and PsycINFO databases yielded 511 studies meeting eligibility criteria. After selective screening for eligibility criteria and excluding duplicates, nine studies remained for detailed analysis. A review of the published research showed that women reported more pain, greater physical impact of disease and treatment, worse fatigue, fatigue severity with interference, and higher symptom burden compared to men. Level of evidence criteria was defined as being strong if two or more high-quality studies resulted in consistent findings. The impact of QOL symptoms based on sex as a biological variable in various hematologic malignancies is an important consideration for providing gender-competent care. Data shows that QOL symptoms differ between genders across several hematologic malignancies. However, research is inadequate regarding the clinical recognition or effective management based on gender. The results of this review will provide information to deliver more personalized and gender-centered care.

Introduction: Treatment-free remission (TFR) is an emerging treatment goal in chronic phase chronic myeloid leukemia (CP-CML). The NCCN guidelines suggest patients must meet the following criteria in order to be eligible for an attempt at TKI discontinuation: use of a TKI for at least 3 years with no history of TKI resistance who have maintained a deep molecular response (MR4 - BCR-ABL IS ≤0.01%) for at least 2 years. The aim of this study was to identify predictors of long-term TFR in CP-CML patients who discontinue TKI therapy at our institution.

Ponatinib is associated with cardiovascular adverse events (CAEs), and its frequency in the real world is limited. In this retrospective study, we examined the survival outcomes and associated toxicities in 78 consecutive ponatinib-treated patients with chronic myeloid leukemia (CML) at the Moffitt Cancer Center from January 2011 through December 2017. The most common non-CAE was thrombocytopenia (39.7%), occurring in a dose-dependent fashion. Eighteen patients (23.1%) experienced some form of CAE, with the most common being arrhythmia (9%) and hypertension (7.7%), whereas 3 patients experienced myocardial infarction (3.8%). Before 2014, most patients were started on ponatinib 45 mg daily. There was an inverse correlation between cardio-oncology referral and the number of CAEs (P = .0440); however, a lower ponatinib starting dose, more frequent dose reduction, and increased cardio-oncology referral all were likely to have contributed to the observed decrease in CAEs after 2014. The response rate and 5-year overall survival (OS) were higher than those observed in the Ponatinib Ph+ ALL and CML Evaluation (PACE) trial (major molecular response, 58.7% vs 40% and OS, 76% vs 73%; median follow-up of 32.5 months). Ponatinib-treated patients with chronic phase-CML did not show a significant improvement with allogeneic stem cell transplantation, whereas those with accelerated phase/blast phase-CML had a much better outcome (median OS of 32.9 months vs 9.2 months; P = .01). These results demonstrate that ponatinib is highly effective. Dose adjustments and increased awareness of the cardiotoxicities associated with ponatinib may help maximize its benefits.

Context Recent advancements in chronic lymphocytic leukemia (CLL) treatment modalities have led to improved patient outcomes, including quality of life (QoL). Such QoL data have primarily been derived from eligible patients undergoing therapy as part of a clinical trial with limited data from real-world patients. Current CLL therapies are not deemed curable, making QoL an important consideration in patient management. Approximately 80% of newly diagnosed patients are managed on active surveillance until International Workshop on CLL criteria for therapy are met. More than 60% of patients are over the age of 65 with comorbid conditions that can be exacerbated either by CLL-related symptoms during active surveillance or by therapy. Clinicians caring for CLL patients should be cognizant of factors impacting QoL in an effort to optimize clinical decision-making while aligning with patient goals. Objectives Systematically review and summarize QoL data from research conducted with adult CLL patients at any point in the disease continuum. Identify knowledge gaps in the literature with implications for future interventional-based research aimed at improving QoL in CLL patients. Design A systematic literature search using appropriate key words was conducted in Embase, PubMed, CINAHL, and PsycINFO to identify studies published from 2009 to 2020. The focus population consisted of CLL patients ≥18 years old affected by any disease stage or treatment status. All studies using self-reported QoL or a symptom instrument were eligible for inclusion. Results Searches of Embase, PubMed, CINAHL, and PsycINFO yielded 445 studies with 54 meeting eligibility for inclusion. Two-author review is underway in Covidence, with a final report to be presented at the meeting. Conclusions The impact of QoL throughout the CLL disease continuum is an important consideration for patient management. Clinicians should incorporate known concepts affecting QoL into CLL management algorithms as part of a multidisciplinary approach to optimize shared decision-making in patient care. Improved understanding of QoL in CLL patients provides the framework for designing effective interventions to address unmet patient needs. Further QoL research is needed in real-world CLL patients. Recent advancements in chronic lymphocytic leukemia (CLL) treatment modalities have led to improved patient outcomes, including quality of life (QoL). Such QoL data have primarily been derived from eligible patients undergoing therapy as part of a clinical trial with limited data from real-world patients. Current CLL therapies are not deemed curable, making QoL an important consideration in patient management. Approximately 80% of newly diagnosed patients are managed on active surveillance until International Workshop on CLL criteria for therapy are met. More than 60% of patients are over the age of 65 with comorbid conditions that can be exacerbated either by CLL-related symptoms during active surveillance or by therapy. Clinicians caring for CLL patients should be cognizant of factors impacting QoL in an effort to optimize clinical decision-making while aligning with patient goals. Systematically review and summarize QoL data from research conducted with adult CLL patients at any point in the disease continuum. Identify knowledge gaps in the literature with implications for future interventional-based research aimed at improving QoL in CLL patients. A systematic literature search using appropriate key words was conducted in Embase, PubMed, CINAHL, and PsycINFO to identify studies published from 2009 to 2020. The focus population consisted of CLL patients ≥18 years old affected by any disease stage or treatment status. All studies using self-reported QoL or a symptom instrument were eligible for inclusion. Searches of Embase, PubMed, CINAHL, and PsycINFO yielded 445 studies with 54 meeting eligibility for inclusion. Two-author review is underway in Covidence, with a final report to be presented at the meeting. The impact of QoL throughout the CLL disease continuum is an important consideration for patient management. Clinicians should incorporate known concepts affecting QoL into CLL management algorithms as part of a multidisciplinary approach to optimize shared decision-making in patient care. Improved understanding of QoL in CLL patients provides the framework for designing effective interventions to address unmet patient needs. Further QoL research is needed in real-world CLL patients.